Takeda Pharmaceutical (Germany) Today
| TKDA Stock | 12.50 0.20 1.57% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Takeda Pharmaceutical is selling for under 12.50 as of the 29th of November 2024; that is 1.57 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 12.5. Takeda Pharmaceutical has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Takeda Pharmaceutical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Moving against Takeda Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Takeda Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Takeda Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Takeda Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Pres | Christophe Weber |
Takeda Pharmaceutical (TKDA) is traded on Stuttgart Exchange in Germany and employs 47,347 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 39.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Takeda Pharmaceutical's market, we take the total number of its shares issued and multiply it by Takeda Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Takeda Pharmaceutical has 784.48 M outstanding shares.
Takeda Pharmaceutical generates positive cash flow from operations, but has no cash available
Check Takeda Pharmaceutical Probability Of Bankruptcy
Ownership AllocationTakeda Pharmaceutical shows a total of 784.48 Million outstanding shares. About 97.77 % of Takeda Pharmaceutical outstanding shares are held by general public with 2.23 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Takeda Ownership Details
Takeda Pharmaceutical Risk Profiles
Although Takeda Pharmaceutical's alpha and beta are two of the key measurements used to evaluate Takeda Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.7857 | |||
| Standard Deviation | 1.09 | |||
| Variance | 1.2 | |||
| Risk Adjusted Performance | (0.06) |
Takeda Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Takeda Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Takeda Pharmaceutical Corporate Management
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher OReilly | Global Fin | Profile | |
| Seigo Izumo | Chair Board | Profile | |
| Gabriele Ricci | Chief Officer | Profile | |
| Salvatore Alesci | Member Policy | Profile | |
| Iwaaki Taniguchi | Sr Department | Profile |
Additional Tools for Takeda Stock Analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.